Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa (ATLAS)
A Randomized Clinical Trial of Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
A PHASE3 clinical study on HIV I Infection and Sepsis, this trial is ongoing. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 8 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Jul 2025 — Present [monthly]
Unknown PHASE3
Status: Recruiting → Unknown
-
Sep 2024 — Jul 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Recruiting PHASE3
-
Jan 2022 — Apr 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
▶ Show 3 earlier versions
-
Sep 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Virginia
For direct contact, visit the study record on ClinicalTrials.gov .